PMEF
TVTX icon

Point72 Middle East FZE’s Travere Therapeutics TVTX Stock Holding History

Point72 Middle East FZE’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-36,216
Closed -$326K – 1230
2023
Q4 		$326K Buy
36,216
+11,211
+45% +$81.6K 0.01% 941
2023
Q3 		$224K Buy
25,005
+11,587
+86% +$163K 0.01% 995
2023
Q2 		$206K Buy
+13,418
New +$244K 0.01% 1056

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Point72 Middle East FZE's TVTX Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Travere Therapeutics (TVTX) in Q1 2024, closing a stake of 36,216 shares — an estimated $326K sold.

Point72 Middle East FZE first reported a position in TVTX in Q2 2023 and held it in 3 quarters. The position peaked at $326K in Q4 2023. 175 funds tracked by Wall St. Rank hold TVTX as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Travere Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 36,216 Travere Therapeutics shares in Q1 2024, an estimated $326K.
  • Point72 Middle East FZE first reported a position in Travere Therapeutics in Q2 2023 and held it in 3 quarters.
  • Point72 Middle East FZE's Travere Therapeutics position peaked at $326K in Q4 2023.
  • 175 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.